Replies to post #103007 on Biotech Values

[DewDiligence]

I stand by the analysis in #msg-53629665, which is IMO the simplest way to project MNTA’s near-term cash flow.

p.s. You said your post uses three pieces of published data but I see only two: NVS’ cumulative Lovenox development costs and NVS’ 6-week sales projection (which is actually a lower bound). What is the third piece of published data?